Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Mineralys Therapeutics, Inc. (MLYS)

Mineralys ends Tanabe license for lorundrostat, takes back patents, keeps $255M in milestones

Neutral Impact 4 of 5 product/contract Written later

Mineralys Therapeutics and Tanabe Pharma terminated the License Agreement for lorundrostat on October 27, 2026, and Tanabe assigned the related patents and know-how to Mineralys. Mineralys remains obligated to pay Tanabe the milestone payments under a separate Payment Obligation Agreement, and Tanabe keeps a first-negotiation right for Japan. The filing says the company incurred no material early termination penalties, and the $100.0 million change-of-control payment is no longer tied to the license terms that existed before.

Key points

  • License Agreement terminated and Transferred Intellectual Property assigned to Mineralys on October 27, 2026
  • Mineralys still owes Tanabe commercial milestone payments of up to $255.0 million plus up to $10.0 million for a potential second indication
  • Tanabe's right of first negotiation survives for Japan while milestones remain unpaid
  • No material early termination penalties incurred; full agreements to be filed with the 2026 Form 10-K

The filing

CompanyMineralys Therapeutics, Inc. (MLYS)
Form8-K, current report
Filed with the SECOct 29, 2026, 4:08 PM ET
Accession number0001933414-26-000136

Items reported: 1.01 Material Definitive Agreement1.02 Termination of Material Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 29, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.